HOWL
Werewolf Therapeutics Inc

1,032
Mkt Cap
$71.34M
Volume
778,393.00
52W High
$2.75
52W Low
$0.595
PE Ratio
-0.95
HOWL Fundamentals
Price
$1.39
Prev Close
$1.56
Open
$1.52
50D MA
$1.61
Beta
1.75
Avg. Volume
800,304.24
EPS (Annual)
-$1.63
P/B
1.71
Rev/Employee
$40,978.26
Loading...
Loading...
News
all
press releases
Alkermes Q3 Earnings and Revenues Beat Estimates, 2025 View Raised
ALKS tops Q3 earnings and revenue estimates as Vivitrol, Aristada and Lybalvi fuel growth; 2025 guidance raised after strong demand.
Zacks·1d ago
News Placeholder
More News
News Placeholder
BioMarin Beats on Q3 Earnings, Seeks to Divest Hemophilia Gene Therapy
BMRN tops Q3 earnings expectations but misses on sales. The company moves to divest its hemophilia gene therapy, Roctavian.
Zacks·2d ago
News Placeholder
Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil
VKTX posts a wider Q3 loss and no sales, as R&D costs surge and obesity drug studies drive spending higher.
Zacks·7d ago
News Placeholder
Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why
Werewolf Therapeutics (HOWL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks·7d ago
News Placeholder
Werewolf Therapeutics, Inc. (HOWL) Just Flashed Golden Cross Signal: Do You Buy?
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Zacks·2mo ago
News Placeholder
XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates
XOMA Royalty (XOMA) delivered earnings and revenue surprises of +500.00% and +39.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Beyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue Estimates
Beyond Air (XAIR) delivered earnings and revenue surprises of -2.00% and -1.68%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates
CorMedix (CRMD) delivered earnings and revenue surprises of +40.00% and +7.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know
Zacks·5mo ago
News Placeholder
Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates
chainwire·6mo ago

Latest HOWL News

View

Advertisement|Remove ads.

Advertisement|Remove ads.